StockData
NovoCure Ltd logo

NovoCure Ltd (NVCR) stock

NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3031% below fair value
$10.73−0.41 (-3.68%)

Close on Nov 18, 2026Market cap $1.25BP/E –Yield –

NovoCure operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

NovoCure's operating income for the twelve months ending Sep 30, 2026 was -$124.55M. For fiscal 2025 it was -$153.80M. The highest annual figure on record is $30.40M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$153.80M–
FY2024Dec 31, 2024-$170.50M–
FY2023Dec 31, 2023-$232.87M–
FY2022Dec 31, 2022-$89.52M–
FY2021Dec 31, 2021-$44.33M-245.8%
FY2020Dec 31, 2020$30.40M–
FY2019Dec 31, 2019-$914.00K–
FY2018Dec 31, 2018-$33.67M–
FY2017Dec 31, 2017-$39.33M–
FY2016Dec 31, 2016-$115.32M–
FY2015Dec 31, 2015-$104.00M–
FY2014Dec 31, 2014-$80.16M–
FY2013Dec 31, 2013-$64.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$6.17M–
Q2 FY2026Jun 30, 2026-$10.56M–
Q1 FY2026Mar 31, 2026-$67.42M–
Q4 FY2025Dec 31, 2025-$40.39M–
Q3 FY2025Sep 30, 2025-$36.02M–
Q2 FY2025Jun 30, 2025-$39.52M–
Q1 FY2025Mar 31, 2025-$37.87M–
Q4 FY2024Dec 31, 2024-$63.30M–
Q3 FY2024Sep 30, 2024-$32.09M–
Q2 FY2024Jun 30, 2024-$33.58M–
Q1 FY2024Mar 31, 2024-$41.52M–
Q4 FY2023Dec 31, 2023-$51.72M–
Q3 FY2023Sep 30, 2023-$58.25M–
Q2 FY2023Jun 30, 2023-$62.66M–
Q1 FY2023Mar 31, 2023-$60.25M–
Q4 FY2022Dec 31, 2022-$42.98M–
Q3 FY2022Sep 30, 2022-$24.61M–
Q2 FY2022Jun 30, 2022-$21.13M–
Q1 FY2022Mar 31, 2022-$806.00K–
Q4 FY2021Dec 31, 2021-$23.40M-293.5%
Q3 FY2021Sep 30, 2021-$8.55M-156.9%
Q2 FY2021Jun 30, 2021-$12.30M-284.4%
Q1 FY2021Mar 31, 2021-$88.00K–
Q4 FY2020Dec 31, 2020$12.09M+7803.3%
Q3 FY2020Sep 30, 2020$15.02M+289.7%
Q2 FY2020Jun 30, 2020$6.67M+457.5%
Q1 FY2020Mar 31, 2020-$3.38M–
Q4 FY2019Dec 31, 2019$153.00K–
Q3 FY2019Sep 30, 2019$3.86M–
Q2 FY2019Jun 30, 2019$1.20M–
Q1 FY2019Mar 31, 2019-$6.12M–
Q4 FY2018Dec 31, 2018-$8.66M–
Q3 FY2018Sep 30, 2018-$5.25M–
Q2 FY2018Jun 30, 2018-$7.09M–
Q1 FY2018Mar 31, 2018-$12.68M–
Q4 FY2017Dec 31, 2017-$4.51M–
Q3 FY2017Sep 30, 2017-$5.92M–
Q2 FY2017Jun 30, 2017-$15.53M–
Q1 FY2017Mar 31, 2017-$13.37M–
Q4 FY2016Dec 31, 2016-$17.88M–

More NovoCure figures

See a number that looks wrong?